 RedHill Biopharma Announces Last Patient Out for Phase 23 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 23 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE July 19, 2021 RedHill Biopharma Ltd. NASDAQ:RDHL RedHill or the Company, a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 23 study with opaganib ABC294640 1 in patients hospitalized with severe COVID-19 pneumonia NCT04467840. 